Growth Metrics

Northwest Biotherapeutics (NWBO) Non-Current Debt: 2009-2025

Historic Non-Current Debt for Northwest Biotherapeutics (NWBO) over the last 14 years, with Sep 2025 value amounting to $7.2 million.

  • Northwest Biotherapeutics' Non-Current Debt fell 65.27% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.2 million, marking a year-over-year decrease of 65.27%. This contributed to the annual value of $12.4 million for FY2024, which is 38.97% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Non-Current Debt of $7.2 million as of Q3 2025, which was down 21.58% from $9.2 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Non-Current Debt peaked at $25.2 million during Q4 2021, and registered a low of $5.9 million during Q3 2022.
  • In the last 3 years, Northwest Biotherapeutics' Non-Current Debt had a median value of $12.4 million in 2024 and averaged $13.7 million.
  • Its Non-Current Debt has fluctuated over the past 5 years, first soared by 290.64% in 2021, then crashed by 76.18% in 2022.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Non-Current Debt stood at $25.2 million in 2021, then tumbled by 76.18% to $6.0 million in 2022, then spiked by 239.04% to $20.3 million in 2023, then plummeted by 38.97% to $12.4 million in 2024, then tumbled by 65.27% to $7.2 million in 2025.
  • Its Non-Current Debt was $7.2 million in Q3 2025, compared to $9.2 million in Q2 2025 and $7.1 million in Q1 2025.